Form 4: Mirum Pharmaceuticals Director William Fairey Acquires Stock Options and Restricted Stock Units

Director William Fairey of Mirum Pharmaceuticals acquired stock options for 8,779 shares and 5,703 restricted stock units on June 5, 2024.

Summary

• On June 5, 2024, William Fairey, a director of Mirum Pharmaceuticals, acquired stock options for 8,779 shares at an exercise price of $26.30.
• These options vest on the first anniversary of the grant date or will be fully vested by the date of the company's 2025 annual stockholder meeting.
• Fairey also acquired 5,703 restricted stock units (RSUs) on the same date.
• Each RSU represents a contingent right to receive one share of Mirum Pharmaceuticals' common stock and will vest on the first anniversary of the grant date or will be fully vested by the date of the company's 2025 annual stockholder meeting.
• Following these transactions, Fairey directly owns 8,779 shares via stock options and 5,703 shares via restricted stock units.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. It reflects standard executive compensation practices, indicating confidence in the company's future without being overly promotional.

Positives

• The acquisition of stock options and RSUs by a director signals confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule tied to the 2025 annual stockholder meeting suggests a continued involvement and interest in the company's performance by the director.

Industry Context

Stock option and RSU grants are common practices in the pharmaceutical industry to incentivize and retain key personnel, aligning their interests with those of the shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the pharmaceutical industry, often benchmarked against peer companies of similar size and stage of development.
• RSUs are also commonly used to provide long-term incentives, with vesting schedules typically tied to continued employment and/or performance milestones.
• Comparing the size of the grant (8,779 options and 5,703 RSUs) to grants made by comparable companies would require further analysis of Mirum's compensation policies and peer group data.

Stakeholder Impact

• The acquisition of stock options and RSUs by a director can positively influence shareholder sentiment, as it aligns the director's interests with the company's long-term success.
• Employees may view this as a positive sign of leadership commitment.

Key Dates